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 β-sitosterol/poly(ethylene glycol)-block-poly(lactic acid) (PLA-b-PEG) 
complexes were prepared by solution blending in purified water and ethanol. The mixture 
of water and ethanol is a suitable solvent system for the two components. The compound 
was studied by using Nuclear Magnetic Resonance (NMR) spectroscopy and Differential 
Scanning Calorimetry (DSC). β-sitosterol is a drug that may reduce the swelling of 
benign prostatic hyperplasia (BPH) and diminishing inflammation. However, it is 
hydrophobic and difficult to deliver in aqueous solution. Since PLA-b-PEG has 
amphiphilic properties, the complex described here may enhance delivery of this drug for 




Proton NMR (1HNMR) of the complexes shows that the methylene (CH2) protons 
of the PEG, the (-O-CH-) of PLA, and (CH3) of PLA are slightly shifted because of its 
non-covalent interaction with β-sitosterol. The complex formation was supported by 2-D 
NMR (NOESY) spectroscopy. NOESY spectra show cross peaks, indicating the 
interaction between the two components.  
DSC of the complexes shows thermal characteristics that are different from the 
individual components. In particular, the PEG in the complex shows a lower melting point 
and decreased crystallinity compared to the pure PEG. The melting point is lowered from 
57°C to 55.3 °C for the PEG-b-PLA/β-sitosterol (5%) complex. Under the same condition, 
the melting point of PLA dropped to 130 °C.  
The atomic force microscopy surface shows changes in the surface morphology of 
the copolymer from crystalline to amorphous when incorporated with the drug. NMR, 
DSC, AFM, and MTT assay studies suggest the formation of a relatively stable β-
sitosterol/poly(lactic acid)-block-poly(ethylene glycol) complex. The cell proliferation 
assay (MTT assay) suggests significant inhibition of the stimulation of growth of prostate 
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                                                        INTRODUCTION 
 
1.1 Prostate Cancer 
 
 Prostate cancer is the one of the most diagnosed cancer in the world,1 whereas  the 
number of prostate cancer survivors has been increasing in the past decade by an 
estimated 200,000 men every year.2 The prostate cancer survivor people in the US 
approached 2.8 million survivors in January 2012.2 Most of them (62%) are age 70 and 
older with multiple comorbid conditions.3 This enhance in prostate cancer survival rates 
is due to the presence of different treatment options including radiotherapy, 
chemotherapy, surgery, hormone therapy, immunotherapy, and in many cases, a 
combination is needed to produce the intended curative results.  
 A patient’s prognosis depends on early detection, complete surgical removal, and 
effective radiotherapy, chemotherapy, or other treatments. Unfortunately, each of the 
treatments has advantages and disadvantages. For example, chemotherapy induces many 
adverse effects such as anemia, hair loss, fatigue, appetite change, nausea, vomiting, 
diarrhea, and constipation. An effective approach to decrease or minimize side effects is 
via multiple or combined treatment options.  
 The most important factor in prostate cancer survival is early and precise 
detection by regular screening examinations. It is difficult to determine who is at risk of 




and obesity; having a healthy diet, and engaging in physical activity can decrease the 
incidence of cancer.4 Once cancer is detected, it is important to reduce the swelling 
related to the existing inflammation before starting any treatment. Phytosterols are 
medications that diminish inflammation. 
 
1.2  β-sitosterol 
β-sitosterol has been known for a long time. Pure sterols from simple unicellular 
organisms evolved over the long period into complex sterols that are now found in 
vascular plants. Research studies reported that algae, protozoa, and fungi produce 
ergosterols (methyl sterol). However, plants creat sitosterol (ethyl sterol). Scientists have 
used diverse scientific methods to isolate and purify β-sitosterol from different plants. 
Sitosterol and its derived compounds are widely distributed in various plant species.   
Phytosterols (see Figure 1) are a class of sterols that are found primarily in the 
cell membranes of plants; they are also present in animal and fungi. This group of sterols 
resembles cholesterols structurally, and they often compete with cholesterol for 
absorption during digestion. 
Cholesterol is a major component of the cell membrane, and it determines the 
fluidity of the membrane. Phytosterol serve an important function in the physiological 
wellbeing of eukaryotic organisms and food items that contain phytosterols are essential 
components of healthy diets. There are three forms of phytosterol, which are very 
common in herbal nutrition. These are sigmasterol, campesterol, and β-sitosterol their 
















Figure 1. Chemical structure of phytosterol and their similarity to cholesterol (5-7). 
 
β-sitosterol (see Figure 2) is an important plant phytosterol, whose structure is 
similar to that of cholesterol. It has lipophilic properties and because of this, it can be 
found in oils made from plants and vegetables. β-sitosterol can prevent the absorption of 
cholesterol.8 This attribute has made it the focus of many research studies that are 
targeted at the reduction of cardiovascular risks.9 The structure of β-sitosterol is given.  
Research studies have shown that β-sitosterol has anti-inflammatory properties and it is 
also analgesic in action in animal models. Its anti-inflammatory capacity has been 
compared to that of hydrocortisone, oxyphenbutazone and its analgesic capacities are 
similar to those of aspirin.10 A recent study has also reported that β-sitosterol is 






Figure 2. Chemical structure of β-sitosterol. 
 
According to previous studies, it has been reported that β-sitosterol confers 
diverse beneficial effects on health. One of its most important effects is its anti-cancer 
action. The sterol has the capacity to prevent the uncontrolled cell division that is 
characteristic of cancer and it is especially effective against breast cancer [MCF-7 and 
MDB-MB-231], 5,12 colon cancer,13,14 prostate cancer,15 and leukemia.16 Its mechanism of 
action makes it a potentially effective agent against cancer. It has also been discovered 
that β-sitosterol can decrease the symptoms associated with prostatic hyperplasia.17 
The chemical formula of β-sitosterol is C29H50O and it has a molecular weight of 
414.71 g/mol. β-sitosterol has been a compound of interest to investigators since the early 
20th century and its chemical structure was elucidated in 1931.18 The compound is 
optically active and it contains one double bond. When the double bond is reduced, it 
yields stigmasterol, which is another sterol compound. Although β-sitosterol has low 
reactivity, many derivatives of it have been manufactured as a treatment for obesity, 




1.3  Poly(lactic acid)  
Poly(lactic acid) (PLA) (Figure 3) has a linear structure that is derived from lactic 
acid monomers. It is biodegradable and biocompatible polyester that is obtained from 
renewable sources and it has been approved by FDA (Food and Drug Administration) for 
medical use. PLA’s hydrophobicity makes it a perfect candidate for the construction of 
the hydrophobic section of micelles. PLA has three kinds of stereoisomers; these are 





  Figure 3. Chemical structure of poly(lactic acid). 
 
PLA combined with PLGA copolymers are usually favored as good choices in the 
production of micro and nanoparticulate drug delivery due to their compatibility with 
living tissues and their natural degradation in the body. These copolymers are also used 
as components of various medical devices. Examples of these include tissue screw and 
tacks, tissue regeneration membranes, sutures, bone fixation devices and meniscus, and 
cartilage repair systems. Drugs that are incorporated into the particles usually affect the 
rate at which the particles are broken down; both acidic and basic drugs impart this effect.     
PLAs of low weights [< 3000 g/mol] are typically produced by direct 




of lactide.21 PLAs dissolve easily in organic solvents, such as dichloromenthane, and 
chloroform but not in common alcohols.22 They do not dissolve in water; although PLAs 
with low weights are more water loving and they contain oligomers that can dissolve in 
water to some extent. 23 
Unlike the D enantiomers, the L PLA forms are not soluble in some organic 
solvents such as acetone and acetonitrile; this makes the use of co-solvent very important 
for instance in the process of nano precipitation. PLA has the capacity to associate with 
various hydrophilic substances, for example PEG,24 PMPC poly(2-methacryloyloxyethyl 
phosphorylcholine), 25 PEO poly(ethylene oxide),26 and PNIPAAm poly(N-
isopropylacrylamide)27 to form amphiphilic copolymers and they can also rearrange to 
form micelles. 
 PEG is a most prominent hydrophilic agent because of its many beneficial 
properties, which include: absence of charge, linear form, low immunogenicity, low poly 
diversity and easy activation of conjugation. In aquatic mediums, PEG hydrolyzes into 
hydroxyl-carboxylic acid that is nontoxic, via cleavage of the ester bond. It is then 
converted into water and carbon dioxide through the TCA cycle. This is possible as a 
result of PEG biodegradability, low immunogenicity, good security, and good mechanical 
strength. However, due to its demerits such as weak hydrophobicity, long degradation 
time and low drug loading of polar drugs, its use is limited. Notwithstanding, PEG 
possess many beneficial properties such as high hydrophilicity, antiphagocytosis, 
flexibility, resistance to immunological recognition, non-adsorption of protein and 




Its copolymerization can improve PLA hydrophilicity, degradation rate, and 
crystallization with PEG. This makes it a promising candidate in the development of a 
drug delivery system. The byproducts of PEG-b-PLA copolymer can be removed from 
the body via the kidneys. In small amount, the copolymer is not toxic and it does not 
accumulate in the tissues. One can increase drug loading time, reduce burst effect, 
prolong stay time of drugs in the tissues and prevent attack by macrophages via 
copolymerization of PLA and PEG.  
Renewable and degradable resources such as corn and rice are used in the 
production of PLA. These types of resources can help in reducing the energy crisis that 
emerges from dependence on fossils fuels. PLA and its byproducts [carbon dioxide and 
water] are harmless and non-carcinogenic to the human body. This makes it a suitable 
choice for biomedical applications like sutures, clips, and a drug delivery system. It 
should be noted also that the amount of water required by PLA is competitive with that of 
the best petroleum-based polymers. Lactic acid can be obtained from different sources 
such as corn syrup, molasses, whey, dextrose, and cane sugar. Industrial production 
mainly makes use of the fermentation process (see Figure 4) because the synthetic 
pathways have signification disadvantages such as high manufacturing costs and inability 




















Figure 4. The cycle of PLA in nature. 
 
Heightened interest in PLA is due to some of its beneficial properties, which are 
nonexistent in other polymers. Such properties include compatibility with living tissues, 
easy processing, renewable and energy saving. PLA is used for various purposes such as 
a matrix for surgical implants and drug delivery system. The disadvantages of PLA 
include poor chemical modifiability (lack of readily reactive side chain groups), low 
flexibility and high cost. PLA synthesized by polymerization can be carried out using 
various techniques such as ring-opening polymerization, azeotropic dehydration 
condensation and enzymatic condensation. The methods that are mostly used are ring 




1.4  Poly(ethylene glycol)  
Poly(ethylene glycol) PEG is among the most popular used polymer in polymer-
based drug delivery system. PEG has played essential functions in drug delivery (Figure 
5). It is the most commonly used protective coating for liposomes and nanoparticles that 
are used in drug delivery. It is also used for protecting proteins and some drug molecules. 
            
Figure 5. Chemical structure of poly(ethylene glycol). 
 
PEG polymer is a good choice for prodrug conjugation due to its high solubility in 
water. PEG can have a linear or branched polyether structure with hydroxyl groups at the 
terminal end. It is usually produced by polymerization of ethylene oxide. Monomethoxy 
PEG (m PEG) is mostly used for modification of polypeptides and it is produced by ring-





Figure 6. Schematic presentation PEG-based pro drug with a targeting agent. 
 
 
    The basic unit of PEG is –CH2H2O- and each monomer unit possess a terminal 
oxygen atom and a –CH2CH2- group, which is non-polar. PEG is soluble in several polar 
and non-polar solvents and it has been used as a vehicle for delivering drug molecules. It 
serves to increase their solubility in water and liposomes are said to be PEGylated when 
PEG is used as protective polymer coating for DDLs.  
PEG prodrugs conjugates are important as drug delivery system. Typically, 
compounds with low weights usually diffuse into tissues via endothelial cell layers of 
capillaries. When low molecular weight drugs are conjugated with polymeric carriers that 
have high mass, the result is always prodrugs that have high molecular weights. The 
conjugation process usually changes the mechanism of cellular internalization and builds 
up. Drugs with high molecular weight are taken into the cells primarily by endocytosis, 
which is a slow internalization process compare to diffusion. Endocytosis requires that 




low molecular weight.28 Prodrugs with high molecular weights typically have lower 









Figure 7. Overview of carrier systems for drug delivery. (Adapted from 33) 
 
PEG-drug conjugates are being studied for a variety of molecules and drugs 
including insulin, daunorubicin camptothecin, peptides, and lipids. The main advantages 
of PEG-drug conjugates are reduced protein immunogenicity, the increased residence 
time in the body, reduced enzymatic degradation. All these features ensure that the drug 
reaches the site of action and prevents clearance from the body because it is not 
recognized as the foreign body. Therefore, the majority of conjugated drugs, as well as 





The conjugation of PEG with enzymes looks very promising in antitumoral 
therapy since several enzymes have proven to be active against various types of cancer by 
acting through different mechanisms. Enzymes that are able to reduce plasma levels of 
these tumor target enzymes amino acids (i.e., asparaginase and arginine deiminase) are 
studied as therapeutic agents in cancer therapy. The advantage of enzymes is their great 
specificity. Since the introduction of PEGylation, several antitumor agents, proteins, 
peptides or low molecular weight drugs, have been considered for polymer conjugation 
but only a few have entered clinical phase studies. The majority of the low molecular 
weight PEG-drug conjugates which are in clinical phase is from the camptothecin family, 
namely camptothecin, SN38 and irinotecan.30 
According to Takeuchi et al.31, a variety of in-situ gelling systems based on 
polyethylene glycol has been used for an injectable drug delivery system. Furthermore, 
PEG is known to be biocompatible, non-toxic and it is one polymer that can be used as a 
scaffold.32 
PEG helps in reducing the aggregation of red blood cells and so improves the 
blood compatibility of PEG copolymers that are implanted as cardiovascular devices such 
as stents. It is mainly used in storage of blood and organs.  Temperature-responsive 
systems have become increasingly attractive as injectable drug delivery systems.34 
 
1.5  Poly(ethylene glycol)-block-poly(lactic acid)  
PLA is one of the most popular amphipathic polymers and it is perfect for making 
micelles. PEG-b-PLA micelles have widespread use as drug delivery system for cancer 




toxic, they do not adsorb protein, and they are weakened after intravenous injection. The 
PLA-b-PEG copolymer applications in drug delivery had been intensively researched. 
PLA is the foundation of the polymer, which supplies structural rigidity to the scaffold 
used while PEG has been subjected to many research studies as a result of its capacity to 
inhibit protein adsorption35 (see Figure 8). 
 
         
 
Figure 8. Poly(ethylene glycol)–block-poly(lactic acid) structure. 
 
 
Particles such as solid particles nanoparticles, liposome and biodegradable 
polyesters like PGA and PLA have commonly been used as the tool of delivery in 
biomedical use. Similarly, PLA, gelatin, and PCL are widely used as drug delivery 
systems because they are biocompatible, biodegradable, low toxicity, and better 
encapsulated. However, the two standard methods of erosion for biodegradable polymers 
are heterogeneous and homogeneous. PLA and their copolymer are commonly utilized in 
nanoparticle form in encapsulation processes. 
      The use of PEG and PLA together brings about reduction in the acidity caused by 
PLA degradation and increase in carriers’ hydrophilicity. PEG is capable of inhibiting the 
binding of particle surface to serum. This leads to the reduction in the affinity for 
Reticulo Endothelial System (RES). Diffusivity of water in PLA-b-PEG carriers is also 




incorporated into PLA polymers.36 This observation was made evident by the fact that 
PEG coating does not adsorb plasma protein, leading to minimization of the interaction 
with phagocytic cell and also increasing the rate of blood circulation.15 Therefore, using 
PLA-b-PEG copolymer as a nano-based carrier for drug delivery will be a better vehicle 
for a long time controlled drug release. 
 
1.6  Drug Delivery System   
Drug delivery system (DDS) is a multidiscipline research interest that 
encompasses many fields such as chemistry, biology, pharmacy, material science, etc.37 
Traditional drug delivery has to do with the periodic release of a drug in such a way that a 
specific amount of the drug that has the desired therapeutic effect is maintained.38 
Typically, after the administration of a drug, the major part of it tends to be rapidly 
released and this usually leads to accelerating drug increase in the blood. The discovery 
of how to control the amount of drug that is delivered to the blood per unit time has had 
significant impacts on the practice of medicine.  
Drug delivery system is developed to enhance treatment efficiency and reduce the 
side effect of the drug and it has been used as effective approaches in recent decades 
especially utilizing polymeric micelles. However, polymeric micelles control the release 
profile of drugs by responding to stimuli of the tumor microenvironment such as 
enzymes, pH and temperature. 
Drug delivery is known to be an approach of transporting pharmaceutical 
compounds in the body in order to achieve the therapeutic effect. Furthermore, it is an 




Drug delivery is when a particular route of administration is integrated with dosage and 
there are common ways of drug delivery system, which include sublingual, oral, rectal, 
nasal, trans-mucosal, inhalation and intravenous. In medicine, biodegradable polymers 
are now used to replace and increase the volume of tissue support and additionally used 
in controlling drug release. Thus, these materials are used as microcapsules for the 
hosting of a diversity of drugs such as anti-conceptive, anti-inflammatory, vaccines, 
narcotics, and antagonist.  
Delivery systems such as controlled released polymer system can release specific 
drug doses continuously for a long period. Controlled release systems have some great 
advantages. These include the ability to deliver optimum therapeutic dosage for a long 
period of time, maintenance of optimum drug concentration in the blood, predictable 
release of drug for a long period of time, enhancement of activity for those drugs that 
have short half-lives, minimization of side effects, prevention of frequent dosing and drug 
wastage, and optimization of therapy and better patient corporation. Regulatory bodies 
have given their approval to some drug delivery systems to be used in humans and these 
have been of immense benefits to patients.39 A significant number of approved delivery 
systems make use of polymers. The most popular polymers include poly(ethylene 
glycol), poly(lactic acid) family and its block copolymer with glycolic acid. Combining 
PEG with drug delivery systems or drugs inhibits the human body defense system from 
detecting and rejecting the polymers.40 The precursors lactic and glycolic acids used in 
the preparation of the polymers can be obtained from sugar cane or corn. The precursors 




are compatible with living tissues and their byproducts can be easily removed from the 
human body. PEG, PLA and PLGA have been used in the production of a drug delivery 
system for peptides due to their capacity to protect the drugs from being destroyed by 
enzymes. They have also been utilized in the production of microspheres, which are used 
to deliver drugs to inner ear and vitreoretinal. PLA and PLGA have been objects of 
intensive research in relation to their use as controlled drug release systems.41 
Polymer nanoparticles have limited used as a result of their poor features, which 
include low biodegradation rate, limited flexibility, and copolymer crystallization. For 
instance, when poly(L-lactide is used, the drug released from the drug delivery system 
usually occurs via drug diffusion comparable to those released by drug carriers that 
cannot be degraded. This is due to the low rate of biodegradation and crystalline 
morphology.42 Biodegradation of polymers that leads to polymer erosion occurs when 
bonds that are sensitive to enzymatic or hydrolytic attacks are cleaved in the polymers. 
The rate of drug release in a biodegradable system is controlled by the rate at which the 
polymer used is broken down. Two forms of biodegradation exist. These are surface 
degradation and bulk degradation. During bulk degradation, the matrix of the polymer is 
removed on a gradual basis while its volume fraction remains constant. For bulk 
degradation, the fraction of the polymer in the system reduces over time while major 
changes occur in the polymeric size only when it is totally degraded. The two forms of 
degradation bring about auto-acceleration. Auto-acceleration is said to happen when 




Based on the method of degradation, polymers can also be categorized into either 
enzymatically or hydrolytically degradable polymers. Naturally occurring polymers 
usually undergo enzymatic degradation.43 For polymers broken down via hydrolysis, 
biodegradation occurs gradually through diffusion. The non-crystalline region will be 
broken down first followed by the crystalline area.44 Factors that have impact on 
degradation of polymers include: chemical structure, distribution of multimers, chemical 
composition, ionic groups, chain defects, structure configuration, molecular weight and 
its distribution, morphology, presence of other compounds, processed method used, 
sterilization process, storage history, annealing, site of implantation, shape, adsorbed and 
absorbed compounds, physical factors (change in size and shape, variation in diffusion 
coefficients, presence of cracking, mechanical stress),  physiochemical factors (pH, ionic 
strength, ion exchange) and hydrolysis mechanism.43             
Furthermore, polymeric micelles can maintain suitable diameter size and stable 
nano-topological structure thereby extending the circulation time in the body and at 
tumor sites. It improved accumulation by enhanced penetration and retention effects.37 
Similarly, the release of encapsulated cargos by the therapeutic nanoparticles depends on 
the tumor microenvironment such as higher temperature, acidic pH value in comparisons 
to normal physiological conditions. Thus, pH-sensitive polymeric micelle is one of the 
most promising stimuli-responsive carriers for controlled release for cancer therapy and 
drug delivery. 
Parental drug delivery system is one of the advanced drug delivery system that 




blood instead of crossing intestinal mucosa. However, parental controlled drug released 
system was developed to overcome the problem faced by conventional intravenous 
injections. Microparticles, liposomes, emulsion, and implants have been identified as 
parental controlled release drug delivery systems.12 Approaches used to obtain a constant 
drug level in the blood are controlling the rate of drug absorption and controlling the rate 
of drug excretion.  
Thus, parenteral and implants injections are the commonly used drug delivery 
systems which usually release drugs longer than a week and drug delivery for more than 
a year can be obtained with various implants systems. Parenteral drug delivery system 
use various route of administration such as intradermal, intraperitoneal, subcutaneous, 
intravenous, and intra-arterial. Many factors need to be considered in determining the 
injectable direction of administration for long-term delivery of drugs such as injection 
sites, cost of therapy, area for target injection sites, quality of life, and patients’ limited 
mobility.       
 
 1.6.1  Polymers in Drug Delivery Systems  
Polymers both synthetic and natural have been widely used in the development of 
drug delivery system due to their versatility and characteristics. Natural polymers are 
highly biodegradable, biocompatible and present functional groups (e.g. -NH2, -OH) that 
can be easily modified. In synthetic polymers, their properties can easily be adjusted to 
match a specific application45, 47 and be prepared with tailored compositions. Polymers 
play an important role in conventional formulations by serving as film coating on tablets, 




However, polymers that are utilized along with the bioactive drug molecules include 
cellulose derivatives, poly(ethylene glycol) (PEG) and poly(N-vinyl pyrrolidone).   
The polymeric systems can be used in the release of proteins, drugs and cells and 
polymers that will be used in drug delivery system (DDS) should have set properties that 
make them suitable materials to interact with the human body. Biodegradable polymers 
are commonly used in DDS because once they are introduced into the human systems or 
body, they do not require removal or addition manipulation. Thus, their degradation 
products are normal metabolites of the body, which can be metabolized and cleared from 
the body.48, 49 
Nanoscale drug delivery has shown the ability to encapsulate a variety of 
therapeutic agents such as peptides, protein-based drugs, nucleic acids and small 
molecules (hydrophobic or hydrophilic). Thus, the encapsulation of molecules inside 
nanocarriers will improve the solubility and stability of the drugs which gives an 
opportunity to re-evaluate potential drugs previously ignored because of poor 
pharmacokinetics.50 
  According to Moghimi.51, encapsulated molecules can be released from 
nanocarriers in a controlled manner in order to maintain a drug concentration within a 
therapeutic window. Furthermore, nanocarriers surface can be engineered to increase the 
blood circulation half-life and also to influence the biodistribution while attachment of 
targeting ligands to the surface can result in enhanced uptake by target tissues.52, 53 





➢    The nontoxic and non-immunogenic polymer carrier;  
➢    The linker must be stable during transport but easily cleaved for optimum 
delivery upon arrival at target (frequently achieved using a Glycine-
Phenylalanine-Leucine-Glycine, or GFLG, peptide linkage); 
➢    The ability to target desired tissue by active and/or passive means;54 
➢    Adequate loading/carrying capacity with the potency of the drug [PEG is not 
an ideal carrier as it has only two reactive groups, which leads to a low drug 
payload;55 
➢    MW high enough to ensure long circulation times, but <40 kDa for 
nonbiodegradable polymers to ensure renal elimination following drug release 
[N-(2-hydroxypropyl) methacrylamide (HPMA) has an optimal MW of ~30 
kDa.55 
The traditional approach to synthesizing polymer-protein conjugates involves the 
postpolymerization modification of the polymeric carrier, usually PEG, with protein 
reactive end groups that facilitate binding between its pendant groups and those of the 
amino acids in the protein.  
 
 1.6.2  Polymer Drug Conjugate Used for Cancer Treatment  
Cancer is known to be diseases that arise as a result of unregulated growth of 
malignant cells that have the ability or potential to invade other parts of the body. 
According to WHO, Cancer-related death are projected to increase in the future with 




mortality has decreased due to the understanding of tumor biology and improved 
diagnostics devices and treatments. 
In the last two decades, the use of nanotechnology has had significant impact 
on clinical therapeutics of cancer compared to conventional chemotherapeutics agents. 
However, the use of nanoscale drug carriers has addressed the potential to address 
some of the challenges by improving treatment efficacy and thereby avoiding toxicity 
in normal cells due to features such as highly selective accumulation in tumors via the 
enhanced permeability and retention (EPR) and active cellular uptake.57,58 Active 
targeting approach is usually achieved by conjugating nanocarriers, which are made up 
of chemotherapeutics to molecules that bind to overexpressed antigens. The emergent 
of nanoscale drug carriers such as polymeric nanoparticles, liposomes, and micelles 
have demonstrated great potentials clinical impacts. Nanocarriers have many 
advantages as drug carrier system, but show poor bioavailability, inadequate tissue 
distribution, biodegradation, instability in circulation, and potential toxicity raise 
concerns over their safety most especially for long term administration.  
There is a physiologically labile bond between the drug and the polymer. 
Paclitaxel [poly(L-glutamic acid)] is used as a chemotherapeutic agent to treat ovarian, 
breast and lung cancer. It has been studied in phase III trials. It has an ester linkage 
between its 2’hydroxyl group and the carboxylic acid of poly(L-glutamic acid).59  
PEG and PAMAM ([Poly(amidoamine) are covalently conjugated with a 
chemotherapeutic drug Paclitaxel to increase its efficiency as an anticancer drug 




cancer cell, it was found that PEG-based conjugate reduced the activity of the 
paclitaxel by 25-fold and the PAMAM-G4 dendrimer increases its efficiency by more 
than ten times.60  
The major advantage of using polymer-drug conjugates is that the chemical and 
physical properties of polymers can be tuned to increase the efficacy and to reduce the 
toxicity of the drug. The stimuli responsiveness provides the release of the prodrug in 
a controlled manner that avoids undesired side effects, organ damage, and toxicity 
caused by the fluctuations associated with periodic administration. A large number of 
anti-cancer drug-polymer conjugates have been studied for cancer therapy due to their 
promising clinical applications in chemotherapy. In this paper, poly(ethylene glycol) 
(PEG) based anti-cancer drug conjugates are discussed followed by a review of 
different types of PEG-b-poly(ε-caprolactone) (PEG-b-PCL) copolymer-drug 

















2.1  Poly(ethylene glycol) Applications 
 
PEG molecular weight used in a different medical and pharmaceutical range from 
50KDa to 400 Da conjugate with low molecular weight drugs such as an oligonucleotide, 
small molecules, and siRNA. Thus, PEG with low molecular weight can be used for 
various drugs such as nanoparticulate system or antibodies.61    
PEG pharmacokinetic studies on different animals such as dogs, rats, pigs, 
monkeys determined an increase the molar mass of PEG result in a decrease its 
gastrointestinal absorption. It showed in rat intestine, PEG with molar mass 4kDa to 
6kDa are not absorbed over 5 hours while 1kDa of PEG have about 2% absorptive effect. 
However, they mainly excreted by the kidneys after intravenous injection of 1g to 
1kDa.62     
PEG improves the blood compatibility of poly(vinyl chloride) bags and also 
reduce the aggregation of red blood cells. Thus, PEG is usually used in the storage of 
blood and organs.63 Furthermore; PEG can be used as excipients in the pharmaceutical 
preparation for topical, parenteral, nasal, and ocular application. Also, it can be used as 
an ingredients of laxatives.  
 PEG can also be used in micelle formation by covalent bonding to a hydrophobic 




hydrophilic shell that is made allows the escape of micelles by the reticuloendothelial 
system, which enables micelles to have more time in circulation as in the case of 
PEG/PCL and PEG/PLA micelles.64 
 It can also be used to increase liposome stability and increase resistance time in 
circulation, which allow them not to be detected by the RES system. Furthermore, gelatin 
nanoparticles usually covered by PEG increases the residence time of gelatin 
nanoparticles. 
 
2.2  PEG–B-PLA Copolymer Synthesis and its End-Group Derivatives 
 2.2.1  The PEG and Lactide Ring Opening Polymerization 
 The process of ring-opening polymerization is used for the synthesis of polymers, 
which occurred between the PEG and its end product derivatives (see Figure 9), which 
includes lactide or methoxy polyethylene glycol (mPEG). 21 Thus, the commonly used 
catalyst for this process is in salt, which have high catalytic efficiency. However, acetic 
acid bismuth is used as an initiator of this reaction because of the toxicity of the heavy 
metal compounds. It was observed that changing the proportion of monomers and 
initiators can control the length of the polymer chain and copolymerization system of L-
lactide and PEG tetramer. 
 
 




 2.2.2  Anionic Ring-Opening Polymerization 
 The catalyst used in the anionic ring opening polymerization includes sodium 
alkoxide, potassium alkoxide, and butyl lithium. According to Otsuka et al.65, α-acetal-
PEG–b-PLA block copolymer is synthesized through anionic ring opening 
polymerization from lactic acid and ethylene oxide as reactant while 3,3-diethoxy-
potassium propanol is used as an initiator. 
 
 2.2.3  Synthesis of PEG-b-PLA End Group Derivatives 
 According to Pulkkinen et al.66, modification of hydroxyl end of PEG usually 
improve the physical and chemical properties of PEG-PLA copolymers for better loading 
of hydrophobic drug, protein drug and gene. Thus, PEG-b-PLA common ends derivatives 
include propylene acylation, hydroformylation, and animation. 
 
2.3  PLA-b-PLGA Drug Encapsulation Development 
 The level of a drug can be maintained within the desired range by the controlled 
release and encapsulation of a drug in a polymeric matrix and this will increase the 
therapeutic activity, reduce the number of administrations necessary and decrease the side 
effect of the drug.67 Furthermore, the process of encapsulation has been used to develop a 
wide variety of biologically active agents from low molecular weight steroids to high 
molecular weight peptides. According to Sutton, the new techniques of using nanometer-
sized amphiphilic,68 PLA-PEG polymeric micelles is known to provide a controlled and 
targeted way to deliver encapsulated anticancer drugs thereby increasing the amount of 




 There are three methods used to prepare PLA-b-PEG conventionally: solvent 
evaporation and emulsification method, solvent displacement method, and the salting out 
method. Furthermore, one of the clinical uses is the transportation of PLA-b-PEG 
micelles by the Genexol micelles system and its uses methoxy-PEG-b-PLA to 
encapsulate paclitaxel. 
 
2.4  Interaction between Drug and Polymer 
 The interaction that occurs between polymer and protein contributes to the 
efficiency of encapsulation. Thus, encapsulation of protein is better within the polymers 
that carry free of carboxylic acid end group when compared with-end capped polymers 
and they are capable of ionic interaction. Moreover, if protein interacts with the polymer 
through hydrophobic interaction, the hydrophobic end-capped hydrophobic groups are 
more advantageous in increasing encapsulation efficiency.  
 In some cases, the interaction between polymers and protein can be mediated by a 
co-encapsulated excipient and encapsulation efficiency usually increases when tetanus 
toxoid in PLGA microparticles is co-encapsulated with gamma-hydroxypropyl 
cyclodextrin (g-HPCD). Thus, gamma-hydroxypropyl cyclodextrin function by 
increasing the interaction by accommodating side chain amino acid of the toxoid into its 
cavity and interacting simultaneously with PLGA through hydrogen bonding forces and 
van der Waals. 
 
2.5  Drug Delivery with β-sitosterol 
 The mechanism of β-sitosterol for the treatment of multifactorial and complex 




multiple signaling pathways. Thus, the anticancer activities of β-Sitosterol are associated 
with activation of the sphingomyelin cycle, cell cycle arrest and stimulation of apoptotic 
cell death. Therefore, β-sitosterol as a natural product has remained neglected despite its 
anticancer activities because when compared with other chemotherapeutic drugs, it has 
low in-vitro efficacy. 
 According to studies, β-sitosterol and its derivatives have been used to enhance 
drug absorption and excipient to stabilize drug release.69 Furthermore, the liposomal 
formulation that contains β-sitosterol decrease colonies of metastatic B16BL6 melanoma 
cells found in the lungs of treated mice and also increases natural killer cell activity.70 
According to Cella et al.71, PEG-PLA or PLGA can encapsulate β-sitosterol in the inner 
hydrophobic core by projecting its hydrophilic shell to the aqueous environment thereby 
enhancing the β-sitosterol solubility in the aqueous phase. Thus, due to nanoparticles 
small size the drug can be concentrated at the diseased sites through retention effect and 
hypothesized enhanced permeability thereby enhancing its anticancer efficacy by several 
fold. 
 In high-performance liquid chromatography (HPLC), sterol mobility is increased 
by side chain double bond and this reflected decreased hydrophobicity of the molecule. 
However, the hydrophobicity change is depended on the position of the side chain double 
bond. Thus, the double bond found at C22 of sterol was more hydrophobic than sterols 
with the double bond at the location of C24. Furthermore, hydrophobicity is increased 
and HPLC mobility is decreased with an increase in the side chain length by the addition 




 According to Sjöström et al.72, it has been reported that β-sitosterol can be used to 
test the efficacy in emulsion form and also act as a model drug for novel formulation.73 
Also, it can be used for formulation additive for stable micelle formulation. It enhances 
the release of drug from gel preparation, sustainability of hormone release, and activity in 
phyto-vesicle preparation. β-sitosterol in combination with another drug enhances 
intestinal and nasal absorption or the delivery of medication to the target organ such as 
the liver.74 
 
2.6  The Release of PEG–b-PLA Block Copolymer Nanoparticles 
 Generally, the release mechanisms of nanoparticles and PEG-b-PLA are similar 
and the three common mechanism include diffusion release, nanomatrix degradation or 
diffusion/degradation collaborative process,24 and desorption and adsorption of drugs on 
nanoparticles surface. However, the release of drugs mainly depends on diffusion by 
nanoparticles matrix, desorption of drugs absorbed on the interface or surface, diffusion 
of bond compounds, and dissolution of nanomatrix. Thus, the process of release of drugs 
is controlled by matrix degradation and drug diffusion. The release mechanism of most 
nanoparticles can be divided into two phases: controlled release phase and burst release 
phase. 
 Burst release phase is the process where drugs diffuse quickly in the solvent 
medium due to weak bonding onto the surface of nanoparticles with larger surface area. 
However, the drugs are not uniformly distributed in the matrix and the drug release by 




delivery system. Furthermore, the drug released depends mainly on matrix degradation 
when the diffusion rate is low.  
 According to Li et al.75, volatile dialysis method was used to prepare all trans-
retinoic acid loaded nanomicelles utilizing the mixture of ethanol (with the proportion of 
9:1) as the release medium and phosphate-buffered saline (PBS) (pH 7.4) and analysis of 
nanomicelles release mechanism were determined. However, it was discovered that the 
burst release occurred in the first 15h following the controlled release. In this case, the 
nanoparticles were complete but not degraded, but the drug release mechanism was 
considered as diffusion after dissolution. In another method, the drug-loaded 
nanomicelles were incubated in PBS and their molecular weight was determined using 
nuclear magnetic resonance. However, it was discovered that the degradation of 
nanomicelles occurred slowly and the time of degradation was 30.1% of mPEG2–b-
PLA16 and 27.6% of mPEG5–b-PLA5 for more than 30 days. Conclusively, all-trans 
retinoic acid-loaded mPEG–b-PLA nanomicelles release mechanism largely depends on 
the drug diffusion rather than matrix degradation. 
 
2.7  Factors that Determined the Drug Release of PEG–b-PLA Copolymer    
  Nanoparticles 
 
 The block copolymer of PLA-b-PEG is known to be an amphiphilic polymer with 
excellent stability, good compatibility. Thus, the solubility of insoluble drugs is increased 
by PEG hydrophilic layer, prevent the protein adsorbed on the nanoparticles surface, 
make nanoparticles unrecognizable by the reticuloendothelial system as foreign bodies, 
and thereby show a characteristic of large circulation. Many factors were involved in the 




2.7.1  PEG-b-PLA and PEG or PLA Chain Length, Molecular Weight Ratio   
  in the Polymer 
 
 Changing the molecular weight of PEG and the concentration of PLA and PEG 
can be used to control the chain length of PEG or PLA. Thus, the longer the chain length 
of PLA, the larger the size of nanoparticles and the drug loading of hydrophobic drugs. 
Also, increase in copolymers PEG contents and average molecular weight of PLA–PEG–
PLA will determine the amount of drug release from nanoparticles and these could be 
potentially be controlled by changing the PEG molecular weight and contents and total 
MW of the copolymer. 
 According to Yang et al.76, the longer the PLA chain length, the larger the drug-
loaded micelles and diameter of micelles. Moreover, an in-vitro test showed that the 
longer the PLA chain length, the higher the interaction that occurred between 
hydrophobic drugs and PLA chain and the slower the drug release rate of micelles would 
be. Furthermore, the greater the PEG molecular weight, the longer the PEG molecular 
chain length will be and also the structure will be stable. 
 
 2.7.2  PEG–b-PLA Copolymer Nanoparticles Drug Loading 
 Drug loading of PEG-b-PLA block copolymer nanoparticles is one of the major 
factors that influence drug release. Huh et al.77 studied the relationship between the drug 
loading and micelles stability and it was discovered that due to the incorporation of 
hydrophobic drugs, micelles hydrophilic-hydrophobic balance was destroyed thereby 








  2.7.3  PEG–b-PLA Block Copolymer Nanoparticles Particle Size 
 Adjusting the PLA-b-PEG ratio and PEG chain length will change the PEG-b-
PLA copolymer nanoparticles size. Thus, different size of PLA-b-PEG copolymer will 
lead to different diffusion or degradation rate of nanomatrix, which can result in 
differences in drug release. 
2.7.4  PEG–b-PLA Copolymer Nanoparticles Preparation Methods and  
  Conditions 
 
 Different types of technological methods used in the preparation of nanoparticles 
will influence the drug distribution, crystal shape of polymer and stability in the carrier 
materials thereby changing the particles size surface morphology, internal compactness 
and influence the rate and degree of drug release. 
 
2.8  Preparation of PED-b-PLA Copolymer Nanomicelles 
2.8.1  The Preparations of PEG–b-PLA Copolymer Nanomicelles Depend  
 Mainly on Hydrophilicity of Copolymers  
 
 The hydrophilic copolymer can form micelles by self-assembly in water and the 
commonly used method is direct dissolution method. Film rehydration method is another 
method used in the preparation of PEG-b-PLA copolymer nanomicelles. When the 
copolymers and drugs were dissolved in a volatile solvent in other to form a membrane 
after vaporizing solvent and the formation is micelles is possible after adding water or 
buffer solution as well as stirring and dissolving copolymer membranes.  
 
2.8.2  PEG–b-PLA Copolymer Polymersomes Preparation 
 A method used in the preparation of liposomes includes ultrasonic dispersion 




adopted the solvent injection method to prepare amphotericin B-loaded polymersomes. In 
film rehydration methods, an organic solvent is used to dissolve copolymers and after 
rotary evaporation of an organic solvent, a membrane is formed. Copolymer 
polymersomes are formed after adding buffer solution and continue stirring with 
extrusion and sonication. 
 
 2.8.3  PEG–b-PLA Copolymer Nanospheres Preparation 
The method that used in the preparation of copolymer nanosphere includes 
emulsification solvent diffusion method and emulsification solvent evaporation method. 
However, the process is divided into two steps: emulsification: this is when copolymer 
and drugs are dissolved in organic solvent and emulsion is formed by adding water into 
the phase and stirred, and evaporation or dialysis: this is when the organic solvent in the 
emulsion is removed by dialysis or evaporation.  
Venkatraman et al.79 used the emulsification solvent evaporation method to 
prepare the PLA–PEG–PLA nanospheres. Firstly, the copolymer was dissolved in 
organic solvents such as THF, dimethylformamide, and acetone and mixed with 
deionized water by stirring. Thus, the acetone or THF was removed by evaporation while 
dimethylacetamide or dimethylformamide was removed by dialysis. Freeze dehydration 
was finally used to obtain the nanospheres. 
 
 2.8.4  PEG–b-PLA Copolymer Nanocapsules Preparation  
 The common method used in the preparation of PEG–b-PLA block copolymer 




dissolved in water-miscible organic solvent and nanocapsules can be prepared by slowly 
dripping the mixed solvent into aqueous solution by stirring with or without surfactants. 
 
2.9  Application of PEG–b-PLA Copolymer Nanoparticles in Pharmaceutical    
  Preparation 
 
 Both PEG and PLA give advantages to PEG-b-PLA copolymer. The benefits of 
PEG-b-PLA copolymer nanoparticles as drug carriers include: increasing bioavailability 
and reducing the first pass effect, increasing drug loading and encapsulation efficiency, it 
reduces the particle size and burst release while improving targeting, removal by 
reticuloendothelia system thereby prolonging the circulation time of drugs in the blood 
and enhancing stability, according to studies, PEG-b-PLA can also be used as a carrier 
for vaccine, gene drugs and protein most especially in a controlled/sustained release drug 
delivery system and targeted delivery system that could enhance drug efficiency and 
reduce drug resistance.80 
 
2.10  PLA-b-PEG Drug Delivery Applications 
 2.10.1  Controlled and Sustained Drug Delivery System  
 The controlled release system of PEG-b-PLA copolymer nanoparticles utilizes 
mainly diffusion and degradation. In the diffusion-controlled system, the drug is 
dissolved in PLA polymers and drug diffusion controls the release rate through a PLA 
matrix. The drug inside the membrane is required to diffuse to the membrane surface first 
and release successfully while the drug adjacent to the membrane surface is releases 




degradation rate determine the drug release rate due to influence from drug loading 
nanoparticles, PLA chain length, release medium and other factors. According to  
Ishihara et al.81, a PEG–b-PLA and PLA nanoparticle mixture was prepared and loaded 
with betamethasone disodium phosphate by taking a mice with the inflammation as a 
model and anti-inflammatory activity was found to be partly weakened by nanoparticles. 
To maintain the biological activities of antigen, protein and other bioactive substances, 
and PEG-b-PLA nanoparticles cannot change the spatial configuration. In the blood, the 
PLA-b-PEG copolymer nanoparticles loaded with proteins may avoid degradation by 
proteases, reduce the recognition of immune cells and enhance stability so that protein 
activation will not occur easily. The protein drug and gene therapeutic agents 
encapsulated in PEG–b-PLA block copolymer nanoparticles for sustained/controlled 
release may improve therapeutic effects of drugs and the quality of life of patients, and 
consequently, the nanoparticles have become popular carriers for proteins and gene 
drugs. 
 
 2.10.2  Targeted Drug Delivery System 
 PEG–b-PLA nanoparticles with a narrow distribution of particle size have a 
smaller particle size than PLA nanoparticles. Thus, they may accumulate easily in 
inflamed locations and then slowly release the drugs. Ueki et al.82 synthesized and used 
carboxy-PEG–b-PLA block copolymer, which was used to prepare camptothecin 
nanoparticles. The results showed that nanoparticles could effectively improve the 
delivery efficiency of camptothecin to the tumor location. Furthermore, lectin- PEG–b-




retention of the biorecognitive activity of lectin after covalent coupling procedure. 
However, using coumarin as a fluorescent marker, the result showed that lecithin 
modified nanoparticles could be delivered to the brain by nasal administration and the 
coumarin uptake by brain carried by lecithin functionalized nanoparticles was about 2-
fold in different brain tissues compared with that of coumarin incorporated in the 
unmodified ones. Due to the hydrophilic chain of PEG, it can stay longer in the nasal 
cavity and facilitate nanoparticles through cell transit and drugs present in PEG-b-PLA 
nanoparticles can enter the brain through the blood-brain barrier.  
 
 2.10.3  Nano-Particulate Drug Delivery Systems 
 Liposomes: Liposomes are known to be small spherical vesicles that make of one 
or more aqueous compartments and can enclose completely by a molecule that has either 
hydrophobic or hydrophilic functionality. Furthermore, liposomes vary in size, 
composition, surface charge and method of preparation. Also, they can either be single or 
multiple bilayers and that containing one bilayer membrane are termed large unilamellar 
vesicles or small unilamellar based on their sizes. 
 Thus, liposomes are useful in systemic toxicity and prevent early drug 
degradation after administration. Furthermore, liposomes are covered with polymers such 
as polyethylene glycol and they can also be conjugated to ligands or antibodies to 
enhance target specificity. The use of nano and micro-particles in biomedicine and 
especially in drug delivery has plenty of advantages over the conventional system such as 
high-performance characteristics of the products, use of lesser amounts of expensive 




from environmental effects in biological media, and effective treatment with a minimal 
side effect. 
 Microemulsions: Micro-emulsion is known to be an isotopic, thermodynamically 
stable system that is composed of oil, water, and surfactant. They are thermodynamically 
stable. However, their drop size is still below 100nm.  
 Furthermore, microemulsions have been proposed as drug delivery systems 
because they can enhance the adsorption of the drug across the biological membrane. 
However, some of the advantages of microemulsion include increased stability and 
solubility of drugs and ease and economy of scale up. Disadvantages include 
microemulsion systems often require the development of complex systems that may be 
time-consuming, co-surfactant does not have pharmaceutically acceptable toxicity, and 
release of incorporated drug/premature leakage. 
 Nanoparticles: Nanoparticle drug delivery systems are known to be carriers that 
deliver biomolecules or drugs. Thus, transporters function with various morphologies 
such as nanocapsules, nano-micelles, nanospheres, and nano-drugs. Also, the nanomeric 
carriers are made up of sub-micron particles with a size below 1000nm. Nanoparticle 
drug delivery has some of outstanding advantages, which improves the drug delivery 
system. It can show controlled release properties due to biodegradability, ion, 
temperature sensibility of the material and pH. It can penetrate tissue and cells to get to 
the target organs such as lung, spleen, liver, spinal cord and lymph. Due to their ultra-tiny 
volume, Nanoparticles can pass through the smallest capillary vessels and they can also 




prolonged. It has the ability to reduce toxic side effect and improve the utility of drugs. 
They can also entrap biomolecules or drugs into their interior structures or absorb drugs 
or biomolecules into their exterior surfaces. 
 Furthermore, nanoparticles are now widely used to deliver drugs, proteins, 
vaccines, nucleic acids, gene, polypeptides, etc. Also, they have shown huge potential in 
the pharmaceutical, medical, biological applications and the most widely used are the 
aliphatic polyester such as PLA, hydrophilic PEG and their copolymers PLGA. However, 
the degradation rate of these polymers usually corresponds to the drug release rate, which 
can vary from days (PGA) to months (PLA). Similarly, the nanoparticles effectiveness in 
drug delivery depends on some major factors, which include; biological and physical 
stability, amenability to freeze-drying and sterilization, the simplicity of the 
manufacturing process, good tolerability of the components, and the possibility of facile 













3.1  Materials 
 
 Poly(lactic acid) (PLA-5000)-b- poly(ethylene glycol) (PEG-10, 000) diblock 
copolymer was purchased from Polysciences, Inc. Poly(ethylene glycol) (MW 2,000, 
8,000, and 35,000) was obtained from Sigma-Aldrich Chemical Company. -sitosterol 
(Practical Grade M.W. 414.7) was purchased from MP Biomedicals Inc. Benzene was 
purchased from Fisher Chemical Company. Chloroform-D (99.8%) for NMR was 
acquired from Acros Organics Company. Prostate cancer cells LNCaP were purchased 
from the American Type Culture Collection, VA (ATCC# CRL-1740). CellTiter 96® 
Non-Radioactive Cell Proliferation Assay (MTT) was purchased from Promega 
Corporation (Madison, WI) to test the toxicity of the drug on LNCaP cells. 
 
3.2  Materials Purification 
 Poly(lactic acid) (PLA-5000)-b- poly(ethylene glycol) (PEG-10, 000) diblock 
copolymer and. -sitosterol were purified and dried by using freeze-drying for 5 hours. 
High purity nitrogen gas was further dried by flowing via a gas filter column filled with 




3. 3  Methods 
 
 3.3.1  Preparation of PLA-b-PEG Polymeric Micelles 
Dissolve 0.2 mg copolymer in 130 ml distilled water and magnetically stirred for 
6h prepared PLA-b-PEG polymeric micelles.83 After that, the mixture was centrifuged at 
5000 rpm for 10 minutes to remove undispersed copolymer. The obtained solution was 
lyophilized to collect dry PLA-b-PEG and then stored at 4 0C for further use. 
 
 3.3.2  Preparation of β-sitosterol Loaded PLA-b-PEG Polymeric Micelles 
          PLA-b-PEG were used to prepare β-sitosterol /PLA-b-PEG by emulsification/ 
solvent evaporation method. In brief, a 0.2 mg copolymer was dispersed in 130 ml 
distilled water (solution A) and magnetically stirred for 6h to ensure complete 
homogeneity. 0.2 mg β-sitosterol was dissolved in 150 ml ethanol (solution B). 83 The 
solution B was added dropwise to the solution A under magnetic stirring at room 
temperature for 48 h. the obtained mixture was centrifuged at 5000 rpm for 10 minutes in 
order to remove unencapsulated β-sitosterol. A half of obtained transparent solution was 
lyophilized to obtain dry β-sitosterol /PLA-b-PEG. Solution and dry samples were stored 
at 40C for further use.  
 
 3.3.3  Preparation of -sitosteroland Poly(Ethylene Glycol) (MW 2,000, 8,000,  
 and  35,000) Complexes 
 One gram (1g) of polyethylene glycol (MW 2,000, 8,000, 35,000) of different 
molecular weights was added to three different round bottom flasks equipped with 
magnetic stirrers and dissolved in 130 ml distilled water. The solutions were stirred until 




temperature. Also, 0.1 g of -sitosterol powder was dissolved in 150 ml ethanol in three 
separate flasks by stirring for 24 hours at room temperature. Each of the flasks containing 
polyethylene glycol was mixed with a flask containing -sitosterol and stirred overnight. 
The ethanol was removed by nitrogen flushing. Lastly a few drops of benzene were 
added to the flasks and the samples freeze dried to obtain white powders. The powders 
were dried on the vacuum line for 48 hours.84 
 
3.4  β-sitosterol Encapsulation Efficiency 
 β-sitosterol encapsulation efficiency (EE) was calculated by following formula: 
 
EE (%) = Total amount of β-Sitosterol - unencapsulated amount of β-Sitosterol ×100 
Total amount of β-Sitosterol 
 
3.5  Instrumentation 
 3.5.1  Nuclear Magnetic Resonance Spectroscopy 
Proton NMR (1H-NMR) spectra in solution state were obtained using a Bruker 
AVANCE 500 MHz spectrometer at room temperature with chloroform (CDCl3) as the 
solvent. 2D NMR experiments (NOESY) were also carried out using the AVANCE 500 
NMR spectrometer. 
 
 3.5.2  Fourier Transform-Infrared Spectroscopy 
The -sitosterol with copolymer polylactic acid/polyethylene glycol complexes 
were crushed in a mortar and pestle with 98% potassium bromide (KBr) until a fine 
powder was obtained. The samples were molded into pellets and IR spectra recorded 




 3.5.3  Differential Scanning Calorimetry 
Differential Scanning Calorimetry was carried out on a TA instruments DSC 
Q2000 at a heating rate of 10°C per minute over the temperature range of 25°C to 200°C. 
The DSC was calibrated using indium under a nitrogen gas atmosphere. All samples were 
quenched cooled before acquiring the thermograms. The samples were heated to 200°C 
and cooled to 25°C before obtaining the heating cycle at 10°C. The glass transition 
temperatures were reported from the second heating cycle. The heating rate in the first 
and second heating cycles remained the same. 
 
 3.5.4  Atomic Force Microscopy (AFM) 
A Bruker Instrument Atomic Force Microscope (AFM) was used to image  
the composite films using the non-contact mode. Atomic force microscopy provides 
higher resolution data with demonstrated resolution in the order of fractions of 
a nanometer.  
  
 3.5.5  MTT Proliferation Assay 
LNCaP cells were grown in 96-well plate (around 10,000 cells/well) and 
incubated overnight at 37oC and 5% CO2 in RPMI-1640 supplemented with 10% of fetal 
bovine serum (FBS), which purchased from Atlanta Biological, GA. Two sets of LNCaP 
cells were treated with different concentrations (10-60µM) of β-sitosterol, β-sitosterol+ 
PEG and β-sitosterol+Copolymer for 24 hours. One set was treated with nano-particles 
without R1881 (synthetic DHT) and the other set was treated with nano-particles with 
R1881. After 24 hours of treatment, the cellular proliferation assay was performed by 




to the manufacture instructions; 15µl of the dye solution containing formazan salt was 
added to the cells and cells were incubated at 37oC in moisturized conditions for four 
hours. After 4 hours of incubation, 100µl of stop buffer was added to the cells and 
incubated for 1 hour at the same conditions to stop the formazan reaction. After 1 hour 
incubation with the stop buffer, the optical density (OD) was measured by Biotek 
Synergy H1 microplate reader at a wavelength 570nm and at a reference wavelength 








RESULTS AND DISCUSSION 
 
 
4.1  Solid State Characterization of the Complexes 
 
The solid-state characterization studies suggest the formation of water-soluble 
complexes of β-sitosterol/PLA-b-PEG as determined by FT-IR and DSC studies. 
 
 4.1.1  β-sitosterol Encapsulation Efficiency 
The formula that was used to measure the encapsulation efficiency shows that the 
lower -sitosterol ratio result in better complex solubility and increase encapsulation 
performance. At constant size of PLA-b-PEG (10,000/5000), the ratio 10% of -sitosterol 
shows better encapsulation than 20% and 30% (see Table 1).83,85  








10% 0.78 78% 
20% 0.53 53% 





 4.1.2  Fourier Transform-Infrared Spectroscopy 
The FT-IR spectra of the pure β-sitosterol, pure PLA-b-PEG, and the complex are 
shown in (see Figure 10), and pure poly(ethylene glycol and its complex displayed in 
Appendix A (Figure A1).84 The FT-IR of copolymer complex shows that the intensity of 
the aliphatic tail of β-sitosterol (i.e., the C-H stretching 2876 -2900 cm-1) was decreased 
compared to the free β-sitosterol,86,87 whereas the aliphatic tail with poly(ethylene glycol) 







Figure 10. FTIR of (a) -sitosterol, (b) PEG-b-PLA, and (c) PEG-b-PLA/-sitosterol 
complex  
 
The OH group intensity of pure PLA-b-PEG and PEG itself was weak because 
there are only two terminal OH groups compared with many C-O and C-H bonds (see 
Figure 10).88 Additionally, the OH peaks in the PLA-b-PEG/β-sitosterol and PEG/β-
sitosterol is diminished in intensity compared to the free β-sitosterol.89 This suggests the 
formation of a complex. The formation of the complex lowers the possibility of 
intermolecular hydrogen bonding among β-sitosterol molecules because in the complex 







interactions. This observation also suggests the formation of a complex between the two 
components.  
 
 4.1.3  Differential Scanning Calorimetry DSC 
The melting point for PEG in block copolymer is 57 °C and PLA is 170 °C (see 
Figure 11).90,91 The melting point decreased when -sitosterol was mixed with the PEG-
b-PLA copolymer.  The melting point for PEG 2,000, 8,000, and 35,000 are 51.1°C, 
61.5°C, and 62.1°C, respectively (see Appendix A, Figures A2, A3, and A4). The melting 
point decreased when 10% (by weight) of -sitosterol was mixed with different 













The PEG melting point of the block copolymer dropped from 57 to 55.3 0C with 
the ratio of 1 to 0.05 of -sitosterol (see Figure 12). The micelles PEG and PLA block 










Figure 12. DSC thermograms of PLG/PEG//-sitosterol and PLG-b-PEG//-sitosterol.  
(5%, 10%, 20%, 30%) 
  
 
The ratio of -sitosterol effect on the melting point of PEG in the block 
copolymer is shown in Table 2. The decrease in the melting point for PLA is significant. 
It dropped to 103.8°C because the -sitosterol interferes with the PLA. In ratio of 1: 1 of 
the drug, the PLA melting point is slightly decreased (130°C) at a ratio of 1: 0.05 (see 




Table 2. DSC Comparison of the Melting Point of the PEG of PLA-b-PEG and PEG with 




PEG Complex Effect MP 
(°C) 
Difference in PEG MP 
(°C) 
  5% 55.3 -1.8 
10% 52.8 -4.2 
20% 59.2 2.2 
30% 62.5 -5.5 
 
 
Table 3. DSC Comparison of the Melting Point of the PLA of PLA-b-PEG and PLA with 




PLA Complex Effect MP 
(°C) 
Difference in PLA MP 
(°C) 
  5% 130.00 -40.0 
10% 103.80 -66.2 
20%   89.50 -80.5 
30% 118.80 -51.2 
 
In both ratios PEG is slightly affected. The β-sitosterol was better distributed 
within PLA than PEG due to the higher hydrophobicity of PLA compared to PEG, and 
better van der Waals interactions between the β-sitosterol and the PLA methylene groups. 
The insertion of the β-sitosterol in between copolymer chains inhibits the alignment 
required for crystallization. Adding the drug to the PEG-b-PLA lead to decrease in the 
MP until certain point then the melting point start to increase, which mean the cavities of 
hydrophobic PEG-b-PLA micelles are overcrowded with the β-sitosterol and starts to 




sitosterol content was closer to the pure PEG, suggesting that increasing β-sitosterol past 
10% results in a microphase separated system with separate phases of PEG and β-
sitosterol present (see Appendix A, Figure A5). Therefore, the results of our study 
indicate that10% β-sitosterol was distributed very well distributed in matrix and 
interacted well with the PEG through hydrophobic interactions.6  However, the PEG with 
20% and 30% of β-sitosterol formed clusters (almost phase separated) in a PEG matrix 
and thus had poor distribution within complex (see Appendix B, Table B2).84 
 
 4.1.4  Atomic Force Microscopy 
 
 Atomic Force Micrographs of the surfaces of spin-cast samples of β-Sitosterol, 
PEG-b-PLA, and the inclusion complex are shown in Figure 13. The surface morphology 
of the three samples is substa The β-sitosterol surface appeared as amorphous “cracked” 
aggregates. These were similar to the AFM surface morphology observed for 
hydroxylpropyl-β-cyclodextrin and trans-ferulic acid.93 The PEG-b-PLA structure 
displayed crystalline-like structure with cone shape. The inclusion complex surface 
morphology shows the formation of crystalline-like structures with some irregularity. The 
surface morphology of the inclusion complex is significantly different from the 




















Figure 13. AFM of spin cast samples with β-Sitosterol, PEG-b-PLA, and the inclusion 
complex. 
  
4.2  Solution State Characterization of the Complexes 
The administration of the complex as a therapeutic has to be carried out in the 
solution state and therefore, it is necessary to characterize the formation of the complex 
in the solution state. The complex in the solution state was studied by one-dimensional 






 4.2.1  Proton Nuclear Magnetic Resonance (1H NMR) 
1H NMR is beneficial for studying complexes in solution. The peak of the 
OCH2CH2 of PEG was 3.55 ppm, the OCH peak of PLA segment read at 5.14 ppm, and 
the peak of CH3 of PLA was at 1.49 ppm.96 β-sitosterol is insoluble in H2O. The aqueous 
solubility of β-sitosterol (see Figure 14) was increased by the presence of PEG-b-PLA 
copolymer (see Figure 15).88 This observation is consistent with the copolymer’s 
capability of solubilizing hydrophobic compounds in aqueous media as a consequence of 



























Figure 15. 500 MHz 1H NMR chemical spectrum of PEG-b-PLA. 
 
1H NMR spectra of PEG-b-PLA as a function of β-sitosterol are displayed in 
Figure 16.89 As the β-sitosterol was added in different ratios to the copolymer, a 












The same effect appeared with the methyl (CH3) and methoxy group (OCH) of 
PLA, which moved more downfield because of interaction with β-sitosterol. The 
downfield shifts of the protons suggest that the PEG-b-PLA is an electron donor to the β-
sitosterol. 91 The greater the concentration of β-sitosterol gives more interaction that leads 
to increase downfield shifting (see Table 4 and Table 5).  
Table 4. NMR Comparison of Shifting of the O-CH2-CH2 of the PEG with Different 
Ratios of -Sitosterol 
 
 
-sitosterol by weight 
PEG Complex Effect  
(ppm) 
Difference in Shifting  
(ppm) 
  5%   3.60 0.05 
10%   3.70 0.15 
20% 3.76 0.21 
 
Table 5. NMR Comparison of Shifting of the OCH of the CH3 of PLA with Different 
Ratios of -Sitosterol 
 
 
-sitosterol by weight 
OCH PLA Complex Effect 
(ppm) 
CH3 PLA Complex 
Effect (ppm) 
  5% 5.15 1.52 
10% 5.18 1.57 
20% 5.19 1.59 
 
1H NMR spectra of poly(ethylene glycol) as a function of β-sitosterol are 
displayed in Figure A6. As the β-sitosterol was added in the same ratio to different 
molecular weights of polyethylene glycol, a downfield shift the methylene protons of the 
PEG was observed (see Appendix B, Table B3). The downfield shift of the methylene 




 4.2.2  2D Proton Nuclear Magnetic Spectroscopy (NOESY)   
Further evidence for the formation of a complex or a non-covalent adduct was 












Figure 17. 2D NOESY (500 MHz) spectrum of β-sitosterol/PEG/PLA complex in 
CDCl3. 
 
The NOESY spectrum displays cross peaks between the hydrophobic part of 
PEG/PLA (the methylene groups) with the aliphatic tail and with the cyclic head of the β-
sitosterol. The NOESY results suggest that the β-sitosterol may have different possible 




Possible orientations include one of the two ends interacting with the methylene 
groups of the PEG, methoxy, and methyl group of PLA and also an orientation in which 
both ends simultaneously interact with the PEG-b-PLA. The two ends simultaneously 
interacting with the PEG-b-PLA will make for a more stable non-covalent adduct or 
complex because of two sites of interactions is most likely stronger than just one 
interacting site.98,99 
 
 4.2.3  MTT Proliferation Assay 
 Two sets of LNCaP cells were treated with different concentrations (10-60µM) of 
β-sitosterol, β-sitosterol + PEG, and β-sitosterol + copolymer. One set was treated with 
the nano-particles and R1881 (1nM) and the other set was treated without R1881. The 
1% Ethanol (v/v) was used as a vehicle negative control which doesn’t have any toxic 
effects on the cells. After treating the LNCaP cells with 1nM of R1881 for 24 hours, the 
OD of the cells has significantly increased about an average of 40% (see Table 6).100  
Table 6. The average proliferation of LNCaP cells before and after treating with R1881. 
 
Cell line 
Average proliferation Without 
R1881 (OD) 
Average proliferation With 
R1881 (OD) 
LNCaP 0.205 0.306 
 
 The β-sitosterol and β-sitosterol + PEG shows a significant reduction in the OD of 
the cells about 20-30% at 10µM concentration, while it shows about 65% reduction at 




Table 7. The Effect of Different Concentrations of β-sitosterol on LNCaP Cells without 
R1881 
Drug 10µM 20µM 30µM 40µM 50µM 60µM 
β-sitosterol 0.147 0.12 0.1035 0.092 0.09 0.11 
β-sitosterol+ PEG 0.115 0.087 0.075 0.064 0.0685 0.073 
β-sitosterol+ copolymer 0.156 0.124 0.08 0.073 0.071 0.075 
 
 Also, the β-sitosterol + PLA-b-PEG copolymer showed higher reduction about 
67% at 50µM concentration (see Figure 18). However, there was no further reduction in 









Figure 18. LNCaP without RI881. 
 
Moreover, after 24 hours of treatment of LNCaP, cells treated with R1881 and β-
sitosterol, β-sitosterol show a reduction in the OD of the cells about an average of 63% at 
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Table 8. The Effect of Different Concentrations of β-sitosterol on LNCaP cells with 
R1881 
 
Drug 10µM 20µM 30µM 40µM 50µM 60µM 
β-sitosterol 0.147 0.12 0.1035 0.092 0.09 0.11 
β-sitosterol+ PEG 0.115 0.087 0.075 0.064 0.0685 0.073 
β-sitosterol+ copolymer 0.156 0.124 0.08 0.073 0.071 0.075 
 
β-sitosterol + PEG shows a reduction in the OD about 50% at 10µM and a 
significant higher reduction in the OD of the cells about an average 78% (see Figure 19) 
which indicates that when β-sitosterol fused with PEG or PLA-B-PEG copolymer, the 
drug toxicity increased to LNCaP cells even when DHT is in the environment which 
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The findings of this study indicate that hydrophobic interactions between the β-
sitosterol and the copolymer poly(ethylene glycol)-b-poly(lactic acid) results in the 
formation of a complex or a non-covalent adduct. The complex or non-covalent adduct is 
water-soluble whereas the pure β-sitosterol is water insoluble.  
The FT-IR of the complex shows that the intensity of the aliphatic tail of β-
sitosterol was slightly decreased compared to the free β-sitosterol. The OH peaks in the 
PLA-b-PEG/β-sitosterol is diminished in intensity compared to the free β-sitosterol.   
The differential scanning calorimetry studies suggest that the complex with 10% 
(by weight) β-sitosterol is well distributed throughout the matrix. Increasing the β-
sitosterol content to greater than 10% by weight in the complex results in the formation 
of β-sitosterol clusters with PEG (20%) and PLA (30%), which diminishes the 
distribution of β-sitosterol throughout the matrix.  
In proton NMR, as the β-sitosterol was added in different ratios to same molecular 
weights of copolymer, a downfield shift the methylene protons of the PEG, methyl, and –
O-CH- group of PLA was observed. The NOESY NMR results demonstrate different 
possibilities for the orientation of how the β-sitosterol interacts with the block copolymer. 




and tail can simultaneously interact with the methylene groups of the PEG. Furthermore, 
β-sitosterol interacts with (-O-CH-) and (-CH3) of PLA. The atomic force microscopy on 
surfaces shows that the PEG-b-PLA surface changed from cone crystal shape to irregular 
morphology after adding the drug, which has amorphous shape.  
Moreover, the data obtained from the MMT proliferation assay, showed that fusing 
β-sitosterol with PEG and block copolymer has increased the drug efficiency to eliminate 
the prostate cancer epithelial cells LNCaP even in the presence of the synthetic DHT 









Beta-Sitosterol Loaded Poly(Ethylene Glycol) Complex As A Comparison Study 
 































































Figure A5. DSC thermograms of 35,000 PEG and 35,000 PEG/-sitosterol (10%, 20%, 





















































Beta-Sitosterol Loaded Poly(Ethylene Glycol) Complex As A Comparison Study 
 
Table B1. Comparison of the Melting Point of the PEG Alone and PEG with the 10% of 
-sitosterol 
PEG MW Polymer MP (°C) Complex MP (°C) Decrease in MP (°C) 
  2,000 51.13 48.86 -2.27 
  8,000 61.49 57.05 -4.44 
35,000 62.06 55.75 -6.31 
 
 
Table B2. Difference in MP between PEG 35,000 (62.06 °C) and the Complex of the 
Drug with PEG 35,000 as a Function of β-sitosterol Content 
-sitosterol by Weight Complex MP (°C) Difference in MP (°C) 
10% 55.75 -6.31 
20% 62.84 0.78 







Table A3. The1H NMR Chemical Shift of the PEG Methylene Groups as a Function of 
Molecular Weight at 10% β-sitosterol Content 
 
 Methylene Methylene protons(ppm)  
PEG Protons(ppm) of PEG with 10%  
(MW) Pure PEG β-sitosterol Δ ppm 
   2,000 3.54 3.58 0.04 
   8,000 3.55 3.58 0.03 
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